Differential phosphoprofiles of EGF and EGFR kinase inhibitor-treated human tumor cells and mouse xenografts

Clinical Proteomics

Volumn 1, Issue 1, 2004, Pages 69-80

  Stover, David R ^a,b,d   Caldwell, Jennifer ^a,b   Marto, Jarrod ^a,b   Root, Karen ^a,b   Mestan, Juergan ^c   Stumm, Michael ^c   Ornatsky, Olga ^a,b   Orsi, Chris ^a,b   Radosevic, Nina ^a,b   Liao, Linda ^e   Fabbro, Doriano ^c   Moran, Michael F ^e  

^a MDS Proteomics   (United States)

^b Novartis Pharma AG ^*  (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Epidermal Growth Factor Receptor (EGFR); Fourier transform mass spectrometry (FTMS); Phosphoproteomics; PKI166; Proteomics

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GROWTH FACTOR; PANITUMUMAB; PHOSPHOPEPTIDE; PK 1166; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FOURIER TRANSFORM MASS SPECTROMETRY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR CELL; XENOGRAFT;

ANIMALIA;

EID: 20144387172     PISSN: 15426416     EISSN: None     Source Type: Journal    
DOI: 10.1385/cp:1:1:069     Document Type: Article

References (30)

1. Ficarro SB, McCleland ML, Stukenberg PT, et al. Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisae. Nat Biotechnol 2002;19:01-305.
2. Oda Y, Nagasu T, Chait BT. Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome. Nat Biotechnol 2001;19:379-382.
3. Zhou H, Watts JD, Aebersold R. A systematic approach to the analysis of protein phosphorylation. Nat Biotechnol 2001;19:375-378.
4. Yarden Y. The EGFR family and its ligands in human cancer, signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37:S3-S8.
5. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy Oncogene 2000;19,6550-6565.
6. Voldborg B R, Damstrup L, Spang-Thomsen, M. & Poulsen, H. S. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997;12:1197-1206.
7. Moscatello DK, Holgado-Madruga M, Godwin, AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995;55:5536-5539.
8. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
9. Scambia G, Benedetti-Panici P, Ferrandina G, et al. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 1995;72:361-366.
10. Simpson BJ, Phillips HA., Lessels AM, Langdon SP, Miller WR. c-erbB growth-factor-receptor proteins in ovarian tumours. Int J Cancer 1995;64:202-206.
11. Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1987;235:177-182.
12. Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin. Invest Drugs 2002;11:837-849.
13. Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997;57:4838-4848.
14. Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;21,499-512.
15. Caravatti G, Bruggen J, Buchdunger E, et al. Pyrrolo[2,3-d]Pyrimidine and Pyrazolo[3,4-d] Pyrimidine Derivatives as Selective Inhibitors of the EGF Receptor Tyrosine Kinase. ACS Symposium Series, ed. 796: Anticancer Agents. Oxford University Press, USA: 2001;231-244.
16. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60,2926-2935.
17. Brandt R, Wong AML, Hynes NE. Mammary glands reconstituted with Neu/ErbB2 transformed HC11 cells provide a novel orthotopic tumor model for testing anti-cancer agents. Oncogene 2001;20:5459-5465.
18. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002;62:1996-2003.
19. Ferrari S, Bandi HR, Hofsteenge J, Bussian BM, Thomas G. Mitogen-activated 70K S6 kinase. Identification of in vitro 40 S ribosomal S6 phosphorylation sites. J Biol Chem 1991;266(33):22770-22775.
20. Ferrari S, Pearson RB, Siegmann M, Kozma SC, Thomas G. The immunosuppressant rapamycin induces inactivation of p70s6k through dephosphorylation of a novel set of sites. J Biol Chem 1993;268(6):4530-4533.
21. Sunnarborg SW, Hinkle CL, Stevenson M, et al. Tumor necrosis factor-α converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 2002;277(15):12838-12845 (2002).
22. Ko TK, Kelly E, Pines J. CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles. J Cell Sci 2001;114:2591-2603 (2001).
23. Marques F, Moreau JL, Peaucellier G, et al. A new subfamily of high molecular mass CDC2-related kinases with PITAI/VRE motifs. Biochem Biophys Res Commun 2000;279(3):832-837 (2000).
24. Lapidot-Lifson Y, Patinkin D, Prody CA, et al. Cloning and antisense oligodeoxynucleotide inhibition of a human homolog of cdc2 required in hematopoiesis. Proc Natl Acad Sci USA 1992;89(2):579-583.
25. Hauck CR, Sieg DJ, Hsia DA, Loftus JC, Gaarde WA, Monia BP, Schlaepfer DD. Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. Cancer Res 2001;61(19):7079-7090.
26. Lu L, Han AP, Chen JJ. Translation initiation control by heme-regulated eukaryotic initiation factor 2alpha kinase in erythroid cells under cytoplasmic stresses. Mol Cell Biol 2001;12:4016-4031.
27. Weed SA, Parsons JD. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 2001;20:6418-6434.
28. Campbell DH, Sutherland RL, Daly RJ. Signaling pathways and structural domains required for phosphorylation of EMS1/cortactin. Cancer Res 1999;59:5376-5385.
29. Mariner DJ. Identification of Src phosphorylation sites in the catenin p120ctn. J Biol Chem 2001;276:28006-28013.
30. Lu Q. δ-catenin, an adhesive junction-associated protein which promotes cell scattering. J Cell Biol 1999;144:519-532.